An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Active, not recruiting at 12 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2019, is one of 10 observational ones, and was the 22nd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, France and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, France and 4 more countries
Ages 6 mo–17 yrs
AbbVie · Sites in India
Ages 18+
AbbVie · Sites in Colombia
Ages 18+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 7 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 62 across the 32 interventional studies, 113 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
5 of the studies in Leukemia, Myeloid, Acute by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05587049AbbVieA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | 2026-11 |
| NCT04086264AbbVieIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | 2027-02 |
| NCT03987958AbbVieA Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | 2027-07 |
| NCT07044687AbbVieStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.
Participants with AML treated with venetoclax in routine clinical practice
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Participant participating in an interventional trial within 30 days prior to starting venetoclax treatment.
Participants in this observational study will receive treatment with venetoclax for AML. The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study.
Overall Survival
Overall survival is defined as the time from the date of first treatment to the date of death from any cause.
Time frame: Time from treatment to death from any cause, up to approximately 30 months
Percentage of participants achieving composite complete remission (CR or CRi)
The percentage of participants achieving CR or CRi will be calculated based on the modified International Working Group (IWG) criteria for AML.
Time frame: Approximately 30 months
Time to transfusion independence
Transfusion independence is defined as the time between date of first venetoclax treatment and absence of red blood cell (RBC) or platelet transfusion for any consecutive 8 and/or 16 week period.
Time frame: Up to 30 months
Percentage of participants achieving transfusion independence
Transfusion independence is defined as the time between date of first venetoclax treatment and absence of red blood cell (RBC) or platelet transfusion for any consecutive 8 and/or 16 week period.
Time frame: Up to 30 months
Percentage of participants treated with venetoclax as compared to participants treated with other approved biologics
The percentage of participants treated with venetoclax in combination with Hypomethylating Agents (HMAs) and Low Dose Cytarabine (LDAC) will demonstrate treatment patterns of prescribing physicians.
Time frame: Up to approximately 30 months
Change in patient reported outcomes for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CORE (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
Time frame: Week 0 to approximately 30 months
Change in patient reported outcomes for the Euro Quality of Life 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L)
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Time frame: Week 0 to approximately 30 months
Plan to share: Undecided
Started Aug 2019 (actual). Primary completion is estimated for Jul 2027, 95 months after the start.
Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's planned 95 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.